13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001121404
Total reported value
$534.0M
$534.0M
9 檔
45.5%
According to the latest 13F quarterly dataset, Sanofi managed an equity portfolio of $534.0M at the end of Q3 2025, spanning 9 distinct U.S. exchange-listed positions.
Sanofi executed strategic sector rebalancing during Q3 2025, establishing 2 new positions while fully exiting 2 holdings and trimming 0 positions.
In terms of portfolio concentration, the top 5 core holdings (including MGTX, NVAX, INBX) accounted for 45.5% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | Stock-Other | 38.56% | -0.58% | — | |
| 2 | NVAX | Novavax Inc | Stock-Healthcare | 22.91% | -4.53% | — | |
| 3 | INBX | Inhibrx Biosciences Inc | Stock-Other | 14.98% | -2.63% | — | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 9.67% | +1.35% | — | |
| 5 | IMRX | Immuneering CORP - Class A | Stock-Other | 7.28% | -1.72% | — | |
| 6 | OMDA | Omada Health Inc | Stock-Other | 4.46% | — | — | |
| 7 | ✓ | Lava Therapeutics NV | Stock-Other | 1.15% | — | — | |
| 8 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.81% | -0.75% | EXIT | |
| 9 | QTTB | Q32 Bio Inc | Stock-Other | 0.19% | +0.11% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INBX | Inhibrx Biosciences Inc | +5.2% | — | Unchanged |
| 2 | ANAB | Anaptysbio Inc | +0.5% | — | Unchanged |
| 3 | QTTB | Q32 Bio Inc | -0.1% | — | Unchanged |
| 4 | ✓ | Lava Therapeutics NV | -0.3% | — | Unchanged |
| 5 | ELDN | Eledon Pharmaceuticals Inc | -0.9% | — | Unchanged |
| 6 | NVAX | Novavax Inc | -3.7% | — | Unchanged |
| 7 | MGTX | MeiraGTx Holdings plc | -11.3% | — | Unchanged |
| 8 | IMRX | Immuneering CORP - Class A | — | NEW | New buy |
| 9 | OMDA | Omada Health Inc | — | NEW | New buy |
| 10 | 1K0 | Igm Biosciences Inc | — | EXIT | Sold out |
| 11 | ✓ | Inozyme Pharma Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sanofi reported a total U.S. public equity portfolio value of $534.0M across 9 disclosed positions in Q3 2025.
During Q3 2025, Sanofi's top holdings by market value included MGTX (38.6%)、NVAX (22.9%)、INBX (15.0%). The largest single position, MGTX, represented 38.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
IMRX
市值: $19.0M
Top Position Liquidated / Trimmed
1K0
前期市值: $1.7M
In Q3 2025, Sanofi made 4 total portfolio adjustments, initiating 2 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.